Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in Humans
The use of antisense molecules to inhibit the expression of disease-causing proteins represents a new paradigm in disease treatment. The molecular target for the antisense molecules, mRNA, is chemically and biologically well defined. This well-defined target is the same for all different possible therapeutic applications, whether the application is antiviral, anticancer, or anti-inflammatory. The specificity with which antisense molecules are capable of inhibiting gene expression, exemplified by the isozyme selectivity demonstrated by [Dean and Mckay 1994], has allowed entirely novel molecular targets to be explored for potential therapeutic applications. Thus antisense molecules have presented an opportunity to exploit a single target for multiple therapeutic indications as well as to explore the utility of inhibiting targets which traditional therapeutic agents could not specifically inhibit.
KeywordsPharmacokinetic Property Antisense Oligonucleotide Peak Plasma Concentration Genital Wart Continuous Intravenous Infusion
Unable to display preview. Download preview PDF.
- Crooke ST, Bennett CF (1996) Progress in antisense oligonucleotide therapeutics.Annu Rev Pharmacol Toxicol 36:107–129Google Scholar
- Geary RS, Leeds JM, Shanahan W, Glover J, Pribble J, Truong L, Fitchett J, Burckin T, Nicklin P, Philips J, Levin AA (1996) Sequence independent plasma and tissue pharmacokinetics for 3 antisense phosphorothioate oligonucleotides: mouse to man. Pharm Res 13:53–95Google Scholar
- Geary RS, Leeds JM, Henry SP, Monteith D, Truong L, Fitchett J, Burckin T, Levin AA (1997) Pharmacokinetic properties of phosphorothioate oligonucleotides. In: Cook PD, Manoharan M (eds) Nucleosides and nucleotides. Marcel Decker, New York (in press)Google Scholar
- Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman J, Geary RS, Levin AA, Shanahan WR (in press) Phase 1 safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp TherGoogle Scholar
- Lebedev AV, Raynaud E, M Beck T, Jaeger JA, Brown BD, Cunningham D, Webb A, McCampbell E, Riley T, Judson I, Woodle MC (1997) Anti-BCL2 phosphorothioate G3139 clinical pharmacology: plasma levels during continuous subcutaneous infusion by HPLC assay. In: Cook PD, Manoharan M (eds) Nucleosides and nucleotides. Marcel Decker, New York (in press)Google Scholar
- Leeds JM, Geary RS, Henry SP, Glover J, Shanahan W, Fitchett J, Burckin T, Truong L, Levin AA (1997) Pharmacokinetic properties of phosphorothioate oligonucleotides. In: Cook PD, Manoharan M (eds) Nucleosides and nucleotides. Marcel Decker, New York (in press)Google Scholar
- Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin R, Schechter PJ, Agrawal S, Diasio RB (1995) Pharmacokinetics of an antihuman immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 58(1):45–53CrossRefGoogle Scholar